Isarna therapeutics presents update from phase 2 better clinical study in wet amd and dme at the euretina meeting

Munich--(business wire)--isarna therapeutics will present an update from its isth0036 clinical development program and the ongoing better study at the euretina meeting in hamburg, germany on september 1st, 2022. prof. marion munk, md, phd, febo, the cmo of isarna therapeutics and a renowned global retina specialist will provide initial positive safety results and efficacy signs from 18 patients treated in the study. to date, the trial has reported a good safety profile for isth0036 with no drug
AMD Ratings Summary
AMD Quant Ranking